Colin F Greineder MD PhD
Colin F Greineder MD PhD
Dr. Greineder is an Assistant Professor in the Departments of Emergency Medicine and Pharmacology. He did his residency training at Michigan and, after a decade at UPenn (completing his PhD in the laboratory of Dr. Vladimir Muzykantov and a post-doc at the Institute for Translational Medicine and Therapeutics), he returned to Michigan in 2018.
Dr. Greineder is an Assistant Professor in the Departments of Emergency Medicine and Pharmacology. He did his residency training at Michigan and, after a decade at UPenn (completing his PhD in the laboratory of Dr. Vladimir Muzykantov and a post-doc at the Institute for Translational Medicine and Therapeutics), he returned to Michigan in 2018.
The driving force behind the Greineder laboratory is the unfortunate reality that many of our most devastating injuries and illnesses - e.g., traumatic brain injury, stroke, cardiac arrest, sepsis, etc. - have no disease specific treatments. To improve future patient outcomes, we need innovative pharmacologic therapies and we need to change the way we do pre-clinical research. Instead of exclusively focusing on mechanisms of disease and therapeutic targets, our group believes it is critical to think about dosing, drug concentration at the intended site of action, the potential for off-target toxicity, and how these things can be measured in large animal studies and early phase clinical trials. In our laboratory, we tackle these issues from the very start of each new project, striving to create both new therapies and technologies to improve the translational potential of other's work.
The driving force behind the Greineder laboratory is the unfortunate reality that many of our most devastating injuries and illnesses - e.g., traumatic brain injury, stroke, cardiac arrest, sepsis, etc. - have no disease specific treatments. To improve future patient outcomes, we need innovative pharmacologic therapies and we need to change the way we do pre-clinical research. Instead of exclusively focusing on mechanisms of disease and therapeutic targets, our group believes it is critical to think about dosing, drug concentration at the intended site of action, the potential for off-target toxicity, and how these things can be measured in large animal studies and early phase clinical trials. In our laboratory, we tackle these issues from the very start of each new project, striving to create both new therapies and technologies to improve the translational potential of other's work.